首页> 美国卫生研究院文献>Journal of Lipid Research >Inhibition of collar-induced carotid atherosclerosis by recombinant apoA-I cysteine mutants in apoE-deficient mice
【2h】

Inhibition of collar-induced carotid atherosclerosis by recombinant apoA-I cysteine mutants in apoE-deficient mice

机译:重组apoA-I半胱氨酸突变体对apoE缺陷小鼠的颈圈诱发的颈动脉粥样硬化的抑制作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The previous studies in our laboratory revealed that seven cysteine mutants of apolipoprotein A-I (apoA-I) have different structural features and biological activities in vitro and in vivo. To investigate the potential cardioprotective effects of apolipoprotein A-I(N74C) [apoA-I(N74C)], we examined the anti-inflammatory, antioxidant, and antiatherosclerotic effects of this cysteine mutant in a rapid atherosclerosis model induced by perivascular carotid collar placement in apoE−/− mice. Lipid-free apoA-I(N74C) showed a significant increased antioxidant potency in low density lipoprotein (LDL) oxidation in vitro and reduced intracellular lipid accumulation in THP-1-derived macrophages, relative to wild-type apoA-I (apoA-Iwt). Mice injected with recombinant HDL (rHDL) reconstituted with apoA-I(N74C) (named rHDL74) through tail veins (40 mg/kg of body weight, three injections) had a significant lower level of serum interleukin-6 (IL-6) and enhanced serum antioxidation compared with mice receiving rHDL reconstituted with apoA-Iwt (named rHDLwt). Moreover, compared with rHDLwt, the rHDL74 in vivo injection resulted in a significant decrease in plaque size, ratio of aorta intima to media, arterial remodeling, and macrophage content in lesions. In summary, intravenous injection with rHDL74 reconstituted with apoA-I cysteine mutant apoA-I (N74C) dramatically delays the development of atherosclerosis induced by perivascular carotid collar placement and reduces vascular remodeling in the carotid artery in apoE−/− mice.
机译:我们实验室中的先前研究表明,载脂蛋白A-I(apoA-I)的七个半胱氨酸突变体在体内和体外具有不同的结构特征和生物学活性。为了研究载脂蛋白AI(N74C)[apoA-I(N74C)]的潜在心脏保护作用,我们研究了该半胱氨酸突变体在快速动脉粥样硬化模型中的抗炎,抗氧化和抗动脉粥样硬化作用,该模型由apoE中的血管周围颈动脉颈环放置引起-/-小鼠。相对于野生型apoA-I(apoA-Iwt),无脂质apoA-I(N74C)在体外低密度脂蛋白(LDL)氧化中显示出显着提高的抗氧化能力,并降低了THP-1来源的巨噬细胞中细胞内脂质的积累)。通过尾静脉注射重组apoA-I(N74C)(称为rHDL74)的重组HDL(rHDL)的小鼠(40 mg / kg体重,三次注射)的血清白介素6(IL-6)水平明显降低与接受用apoA-Iwt重组的rHDL(称为rHDLwt)的小鼠相比,其抗氧化能力增强。此外,与rHDLwt相比,rHDL74体内注射导致斑块大小,主动脉内膜与培养基的比率,动脉重塑和病变中巨噬细胞含量显着降低。总之,静脉内注射重组有apoA-I半胱氨酸突变体apoA-I(N74C)的rHDL74,可显着延缓由血管周围颈动脉颈环放置引起的动脉粥样硬化的发展,并减少apoE -/-的颈动脉血管重构。 sup>小鼠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号